brexucabtagene autoleucel,pivekimab
gilead
['cart,(-cartitude)', 'zuma2']
unknowns
1/ generalisable without maintenance? especially with infection rates following r/g+benda+maint in trial, covid
2/ impaired leukapheresis for cart post benda, however zuma2 data suggests usually ok &gt;6 months (wang et al, poster p1117 #eha2022) 
Clinical haematologist and haematopathologist in Sydney, Australia.